HFS
TSHA icon

Hughes Financial Services’s Taysha Gene Therapies TSHA Stock Holding History

Hughes Financial Services’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41 Buy
+6
New +$36 ﹤0.01% 1640
2026
Q1 		– Sell
-4
Closed -$22 – 1801
2025
Q4 		$22 Buy
+4
New +$19 ﹤0.01% 1218

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hughes Financial Services's TSHA Position: Q2 2026 in Review

Hughes Financial Services opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 6 shares worth $41. The stake represents ﹤0.01% of the portfolio and ranks #1640 among its holdings. This is a return to the name: Hughes Financial Services previously reported a position in TSHA as recently as Q4 2025.

Hughes Financial Services first reported a position in TSHA in Q4 2025 and has held it in 2 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Hughes Financial Services held 6 shares of Taysha Gene Therapies worth $41 as of Q2 2026.
  • Taysha Gene Therapies was a new Hughes Financial Services position in Q2 2026.
  • Taysha Gene Therapies made up ﹤0.01% of Hughes Financial Services's portfolio in Q2 2026, its #1640 holding.
  • Hughes Financial Services first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 2 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Hughes Financial Services's 13F filing for Q2 2026, filed 20 Jul 2026.